Bioharmony Therapeutics, a biopharmaceutical company focusing on the development of novel therapeutics for hard to treat bacterial infections, has signed a collaborative research and licensing agreement with Boehringer Ingelheim, it was reported yesterday.
The contract has been signed to develop bacteriophage lysins for the treatment of multidrug resistant Acinetobacter infections, a frequent cause of hospital-acquired pneumonia and life-threatening blood or wound infections.
Bioharmony licensed this technology from the Rockefeller University. The discoveries are from the laboratory of Vincent A Fischetti, PhD, a faculty member at The Rockefeller University. Recently, the World Health Organisation listed drug-resistant Acinetobacter baumannii to be a critical priority pathogen, causing around 9% of all bacterial infections in intensive care worldwide, against which there are few treatment options available.
Financial terms of the deal have not been revealed.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval